Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for acute COPD exacerbations treated with steroids and antibiotics
2011-002905-31Phase 2Terminated
- Sponsor
- Nycomed
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Change in sputum neutrophil counts from baseline to Day 14. Started Oct 2011; status: terminated.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-002905-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002905-31.